GFM
GF Fund Management Portfolio holdings
AUM
$4.97B
This Quarter Return
-4%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$4.26B
AUM Growth
-$362M
(-7.8%)
Cap. Flow
-$2.11M
Cap. Flow
% of AUM
-0.05%
Top 10 Holdings %
Top 10 Hldgs %
43.71%
Holding
683
New
46
Increased
475
Reduced
93
Closed
17
Top Buys
| 1 |
Philip Morris
PM
|
$43M |
| 2 |
Amazon
AMZN
|
$24.3M |
| 3 |
Palantir
PLTR
|
$16.8M |
| 4 |
Yum China
YUMC
|
$14.4M |
| 5 |
Hims & Hers Health
HIMS
|
$10.9M |
Top Sells
| 1 |
Pinduoduo
PDD
|
$40.6M |
| 2 |
NVIDIA
NVDA
|
$25.7M |
| 3 |
KE Holdings
BEKE
|
$14.3M |
| 4 |
Meta Platforms (Facebook)
META
|
$13.3M |
| 5 |
Coca-Cola
KO
|
$9.83M |
Sector Composition
| 1 | Technology | 42.51% |
| 2 | Consumer Discretionary | 16.26% |
| 3 | Communication Services | 14.17% |
| 4 | Healthcare | 7.8% |
| 5 | Consumer Staples | 6.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
401
Medical Properties Trust
MPW
$2.77B
| $61.7K | ﹤0.01% |
10,235
-126
| -1% | -$760 |
|
402
Broadstone Net Lease
BNL
$3.53B
| $60.9K | ﹤0.01% |
3,571
+145
| +4% | +$2.47K |
|
403
Twist Bioscience
TWST
$1.55B
| $59.7K | ﹤0.01% |
1,520
+274
| +22% | +$10.8K |
|
404
Highwoods Properties
HIW
$3.44B
| $59.5K | ﹤0.01% |
2,008
+82
| +4% | +$2.43K |
|
405
Veracyte
VCYT
$2.55B
| $58.8K | ﹤0.01% |
1,984
+357
| +22% | +$10.6K |
|
406
COPT Defense Properties
CDP
$3.46B
| $58.2K | ﹤0.01% |
2,134
+87
| +4% | +$2.37K |
|
407
Vericel Corp
VCEL
$1.72B
| $56.4K | ﹤0.01% |
1,264
+228
| +22% | +$10.2K |
|
408
Apple Hospitality REIT
APLE
$3.09B
| $55.7K | ﹤0.01% |
4,317
+161
| +4% | +$2.08K |
|
409
Mirum Pharmaceuticals
MIRM
$3.82B
| $55.3K | ﹤0.01% |
1,228
+220
| +22% | +$9.91K |
|
410
Chubb
CB
$111B
| $54.7K | ﹤0.01% |
+181
| New | +$54.7K |
|
411
Waste Management
WM
$88.6B
| $54.6K | ﹤0.01% |
+236
| New | +$54.6K |
|
412
Progressive
PGR
$143B
| $54.6K | ﹤0.01% |
+193
| New | +$54.6K |
|
413
National Storage Affiliates Trust
NSA
$2.56B
| $54.1K | ﹤0.01% |
1,372
+61
| +5% | +$2.4K |
|
414
ImmunityBio
IBRX
$2.27B
| $53.7K | ﹤0.01% |
17,843
+3,211
| +22% | +$9.67K |
|
415
Edgewise Therapeutics
EWTX
$1.64B
| $53.3K | ﹤0.01% |
2,424
+436
| +22% | +$9.59K |
|
416
Four Corners Property Trust
FCPT
$2.73B
| $52.6K | ﹤0.01% |
1,832
+148
| +9% | +$4.25K |
|
417
Recursion Pharmaceuticals
RXRX
$2.01B
| $51.7K | ﹤0.01% |
9,775
+1,759
| +22% | +$9.31K |
|
418
Ligand Pharmaceuticals
LGND
$3.25B
| $50.9K | ﹤0.01% |
484
+87
| +22% | +$9.15K |
|
419
Douglas Emmett
DEI
$2.83B
| $50.7K | ﹤0.01% |
3,171
+129
| +4% | +$2.06K |
|
420
Tarsus Pharmaceuticals
TARS
$2.43B
| $50.2K | ﹤0.01% |
978
+175
| +22% | +$8.99K |
|
421
Denali Therapeutics
DNLI
$2.26B
| $50.1K | ﹤0.01% |
3,685
+663
| +22% | +$9.01K |
|
422
NovoCure
NVCR
$1.37B
| $49.4K | ﹤0.01% |
2,770
+498
| +22% | +$8.87K |
|
423
Harmony Biosciences
HRMY
$2.07B
| $48.5K | ﹤0.01% |
1,460
+262
| +22% | +$8.7K |
|
424
NewAmsterdam Pharma
NAMS
$3.04B
| $48.4K | ﹤0.01% |
2,365
+425
| +22% | +$8.7K |
|
425
Zai Lab
ZLAB
$3.42B
| $48.3K | ﹤0.01% |
1,336
+241
| +22% | +$8.71K |
|